We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CuraGen and TopoTarget A/S have initated patient dosing in a Phase II clinical
trial evaluating PXD101, a small molecule histone deacetylase (HDAC) inhibitor,
as a potential treatment for advanced multiple myeloma, a deadly type of blood
cancer.
Renovis has completed enrollment of patients in its Phase II trial of REN-1654
in the treatment of postherpetic neuralgia (PHN), an often debilitating form
of neuropathic pain that can occur in patients following an outbreak of shingles.
Northwest Biotherapeutics (NWBT) has received clearance from the FDA to begin
assessment of its cell-based dendritic cell product candidate, DCVax-Prostate,
in a Phase III clinical trial.
Wyeth Pharmaceuticals, a division of Wyeth, has announced that the FDA granted
priority review status to the company's new drug application (NDA) for the
investigational I.V. antibiotic Tygacil.
Teva Pharmaceutical has been granted final approval from the FDA for the its
abbreviated new drug application for Glyburide and Metformin HCl tablets,
1.25 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg.
Acute viral infections, including smallpox, may be halted by aiming a drug
not at the virus but at the cellular machinery it needs to spread from cell
to cell -- an approach that might eliminate the problem of antiviral drug
resistance, said researchers supported by the National Institute of Allergy
and Infectious Diseases (NIAID), part of NIH.
Patients with active Crohn's disease who have ceased responding to Remicade
may respond to Humira, according to a new study in the January 2005 issue
of the American Journal of Gastroenterology.